MarketVue®: Eosinophilic Esophagitis
The MarketVue®: Eosinophilic Esophagitis market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:Research for the MarketVue®: Eosinophilic Esophagitis report is supported by 4 qualitative interviews with key opinion leaders, a quantitative survey with 25 U.S. physicians and secondary research.
Geographies covered:United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
Key companies mentioned:• Regeneron Pharmaceuticals
• Sanofi
• AstraZeneca
• Bristol-Myers Squibb
• Ellodi Pharmaceuticals
• EsoCap
• Pfizer
• Dr. Falk Pharma
• Revolo Biotherapeutics
• Amzell Pharma
• EMS
Key drugs mentioned:• Corticosteroids
• Dupilumab (Dupixent)
• Benralizumab (Fasenra)
• Tezepelumab (Tezspire)
• Etrasimod (Velsipity)
• Cendakimab / CC-93538
• APT-1011 / fluticasone propionate
• ESO-101 / mometasone
• Mesalazine
• IRL201104
• Budesonide
• Florence
Key takeaways from the report:
Despite being recognized as a distinct etiology of eosinophilic gastrointestinal disease for less than 30 years, EoE care has evolved to include four treatment options:
• Dietary therapy
• Proton pump inhibitors
• Corticosteroids
• Biologic therapy (Dupixent)
While EoE is marked by the availability of multiple drug classes, findings from REACH’s MarketVue® assessment of the EoE market show that nearly one-third of EoE patients would be eligible for treatment with novel drug classes like Dupixent, according to surveyed gastroenterologists.
Physicians are eager for more diverse EoE treatment options including FDA-approved corticosteroids and new therapies that can improve histologic and symptomatic response. Importantly, EoE patients play an outsized role in treatment selection.
Melissa Curran, Director at REACH: “With few prognostic markers to guide treatment recommendations, treatment selection is primarily patient driven. Physicians usually present all classes of treatments to patients and educate on the pros and cons of each option. Since many EoE patients are young and active, convenience is a key driver of treatment preference.”
The EoE pipeline is ripe with novel treatment options including:
• Ellodi Pharma’s reformulated corticosteroid APT-1011
• Bristol Myer Squibb’s IL-13 cendakimab
• Pfizer’s S1P etrasimod
Despite the flurry of development activity, late-stage failure is common in EoE (e.g., Takeda’s TAK-721, AstraZeneca’s Fasenra (benralizumab), Allakos’ lirentelimab) due to the frequent discord between histological and symptomatic response as one gastroenterologist comments: “I’m a big believer in the histology and what we’ve seen in trials is that symptoms don’t always correlate with histologic remission.”
Please note: the online download version of this report is for a global site license.